Interleukin-8 targeting monoclonal antibody - NovaRock Biotherapeutics
Alternative Names: Anti-IL-8 monoclonal antibody; IL-8 targeting monoclonal antibodyLatest Information Update: 05 Mar 2024
At a glance
- Originator NovaRock Biotherapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin 8 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 19 Feb 2024 Preclinical trials in Haematological malignancies in USA (Parenteral) prior to February 2024 (NovaRock Biotherapeutics pipeline, February 2024)
- 19 Feb 2024 Preclinical trials in Solid tumours in USA (Parenteral) prior to February 2024 (NovaRock Biotherapeutics pipeline, February 2024)